Verona Pharma’s Ohtuvayre: Strong Performance and Growth Potential Drive Buy Rating
Verona Pharma (VRNA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from ...
Investing14d
Roth/MKM initiates coverage on Verona Pharma stock with Buy rating and strong upside potential
Friday - Shares of Verona Pharma (NASDAQ:VRNA) received a positive outlook from Roth/MKM as the firm initiated coverage with a Buy rating and a 12-month price target of $68. The bullish stance is ...
Investing15d
Roth/MKM initiates coverage on Verona Pharma stock with Buy rating and strong upside potential
Friday - Shares of Verona Pharma (NASDAQ:VRNA) received a positive outlook from Roth/MKM as the firm initiated coverage with a Buy rating and a 12-month price target of $68. The bullish stance is ...
Hosted on MSN15d
Roth MKM Initiates Coverage of Verona Pharma plc - Depositary Receipt () (VRNA) with Buy Recommendation
As of December 23, 2024, the average one-year price target for Verona Pharma plc - Depositary Receipt is $47.94/share. The forecasts range from a low of $36.36 to a high of $67.20.
BBC15d
Serie A Hellas Verona 0 Udinese 0 14 minutes played. In progress
Please Note: All times UK. Tables are subject to change. The BBC is not responsible for any changes that may be made. Manager: Paolo Zanetti Formation: 3 - 4 - 1 - 2 Manager: Kosta Runjaic ...